“COVID-19 Study in Bergamo, Italy, to improve clinical outcomes for patients and to generate data for future treatments.”

A sponsored study of the monoclonal antibody siltuximab is being conducted in Italy to see if the therapy can help treat Covid-19 patients who have developed serious respiratory complications.

A compassionate use trial of siltuximab for the treatment of COVID-19 patients has been initiated at the Papa Giovanni XXIII Hospital in Bergamo, Italy.

The trial will be sponsored by EUSA Pharma which will supply siltuximab for the study.

Siltuximab is a monoclonal antibody currently used for the treatment of Multicentric Castleman Disease.

It targets the production of inflammatory cytokine IL-6.

According to initial data from China, IL-6 may have a role in the development of acute respiratory distress syndrome (ARDS) in COVID-19 patients.

The study aims to determine whether targeting this cytokine may improve the clinical outcomes for COVID-19 patients with serious respiratory complications.

The researchers also seek to understand the potential for IL-6 blockade in COVID-19 patients and to generate credible data to guide future research and treatment decisions.

 

KEY POINTS

  1. Siltuximab will be used on a compassionate basis for the treatment of COVID-19 patients with serious complications in Italy.
  2. It is an IL-6 targeted monoclonal antibody that targets the production of inflammatory cytokine IL-6.
  3. Initial data suggest that IL-6 may be involved in the development of respiratory complications as a result of Covid-19.

 

“We are delighted to support this study to investigate the potential for siltuximab to help patients severely ill as a result of Covid-19,” says EUSA Pharma’s chief executive officer Lee Morley.

 

Article source: https://bit.ly/2vMPyWG

 

#ClinicalTrials, #COVID-19, #Siltuximab, #IL-6, #ARDS

 

P.S. Staying up-to-date with what’s new in Clinical Trials? Get the latest articles summarized and delivered free to your e-mail inbox. Click here to learn more.

Latest news

ACTide by Nubilaria against COVID-19

DECEIVER trial for COVID-19 related ARDS intensive care

Read more
Nubilaria for EUROLogin2020

EUROLogin2020

Read more
Nubilaria ACTide @ SCOPE Virtual 2021

SCOPE – Summit for Clinical Ops Executives

Read more
Nubilaria Christmas wishes 2020

Merry Christmas and Happy new Year

Read more

Want more information about our solutions?
Contact us today.

I've read and accept theTerms and Conditions and the Privacy Policy
   I would like to receive information about products and services via traditional mail, telephone, email and automated communication systems